Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Single-Dose Naldemedine in Opioid-Induced Bowel Dysfunction
NCT01122030Phase 2Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- May 2010
- Primary completion
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of naldemedine in opioid-induced bowel dysfunction (OIBD) (6 cohorts), sponsored by Shionogi & Co., Ltd. Primary endpoint: Number of Participants With Adverse Events. Started May 2010; status: completed.
02
Drugs
naldemedine
03
Conditions
opioid-induced bowel dysfunction (OIBD)
Beyond the preview
Go deeper on NCT01122030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01122030.